Xcout Intel
ImmunOs Therapeutics AG competitors & alternatives
The 12 closest competitors and alternatives to ImmunOs Therapeutics AG among biotechnology companies — ranked by similarity to what ImmunOs Therapeutics AG actually does, not by market-cap band.
Subscribe to see ImmunOs Therapeutics AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
ImmunOs Therapeutics AG at a glance
ImmunOs Therapeutics AG is a biotechnology company headquartered in Switzerland. It has raised at least $85M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series C, raised $11M in September 2024. Xcout tracks 5 named people at ImmunOs Therapeutics AG, including Daniel Vasella (VICE CHAIRMAN).
ImmunOs Therapeutics AG leadership
- Daniel VasellaVICE CHAIRMAN
- Reinhard Ambros, PhDCHAIRMAN OF THE BOARD
- Christoph Kocher, PhDDirector
- Markus Hosang, PhDDirector
- Steve Tregay, PhDDirector
ImmunOs Therapeutics AG funding rounds
At least $85M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $11M | — | |
| Series B | $74M | 10 named | |
| — | Undisclosed | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 ImmunOs Therapeutics AG competitors
Ranked by semantic similarity — how close each company is to ImmunOs Therapeutics AG by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
Similar biotechnology company
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
Similar biotechnology company
iOmx Therapeutics AG is a biopharmaceutical company located in Martinsried near Munich, Germany, dedicated to discovering and developing next-generation targeted cancer immunotherapies.
Similar biotechnology company
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
Similar biotechnology company
Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.
Biotech
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Similar biotechnology company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, with an additional office in Belgium. The company focuses on discovering and developing novel immuno-oncology therapeutics for cancer treatment.
Similar biotechnology company
Mysthera Therapeutics AG is a biotechnology company headquartered in Basel, Switzerland, focused on developing first-in-class, oral therapeutics to treat inflammation-driven and related diseases.
Similar biotechnology company
Immunomic Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company founded in 2005 and headquartered in Rockville, Maryland, that develops innovative immune therapies.
Biotech
Nouscom is a private, clinical-stage oncology company headquartered in Basel, Switzerland, with additional research facilities in Rome, Italy. The firm is dedicated to re-defining cancer immunotherapy through its proprietary viral vector platform.
Similar biotechnology company
Brenus Pharma is a pioneering clinical-stage biotech company headquartered in Clermont-Ferrand, France. The firm focuses on developing innovative immunotherapies aimed at preventing cancer recurrence and addressing solid tumors.
Similar biotechnology company
IpiNovyx Bio, Inc. is a biopharmaceutical company that discovers and develops targeted proteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Utilizing a proprietary technology platform, the company focuses on advancing selective and reversible immunoproteasome inhibitors to create safer and more effective therapies for patients.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ImmunOs Therapeutics AG and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ImmunOs Therapeutics AGand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →